Vor Biopharma (NASDAQ:VOR) Upgraded by Zacks Research to “Hold” Rating

Zacks Research upgraded shares of Vor Biopharma (NASDAQ:VOR) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Several other research firms also recently weighed in on VOR. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 15th. HC Wainwright boosted their price target on Vor Biopharma to $52.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Stifel Nicolaus upgraded Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research note on Wednesday, September 24th. Finally, Robert W. Baird upgraded shares of Vor Biopharma from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $20.00 to $64.00 in a research note on Wednesday, October 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $76.50.

Vor Biopharma Stock Down 3.1%

Shares of NASDAQ VOR traded down $0.31 during trading on Tuesday, reaching $9.75. 864,012 shares of the stock were exchanged, compared to its average volume of 437,989. The company has a market cap of $66.79 million, a P/E ratio of -0.04 and a beta of 2.02. The business’s 50-day moving average price is $30.11. Vor Biopharma has a twelve month low of $2.62 and a twelve month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Insiders Place Their Bets

In other Vor Biopharma news, major shareholder Reprogrammed Interchange Llc sold 447,278 shares of the company’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $1.54, for a total value of $688,808.12. Following the completion of the sale, the insider directly owned 32,781,209 shares in the company, valued at $50,483,061.86. This represents a 1.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. sold 260,859 shares of the business’s stock in a transaction on Friday, October 17th. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01. Following the completion of the sale, the director directly owned 15,104 shares in the company, valued at $443,906.56. This represents a 94.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,431,718 shares of company stock valued at $62,090,254 in the last quarter. 0.45% of the stock is currently owned by insiders.

Institutional Trading of Vor Biopharma

Large investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. grew its stake in Vor Biopharma by 218.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock valued at $61,000 after acquiring an additional 58,247 shares in the last quarter. XTX Topco Ltd bought a new stake in Vor Biopharma in the second quarter worth approximately $66,000. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma in the first quarter worth $100,000. Jane Street Group LLC acquired a new position in shares of Vor Biopharma during the 1st quarter valued at about $140,000. Finally, BNP Paribas Financial Markets grew its holdings in Vor Biopharma by 497.3% during the third quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock valued at $296,000 after purchasing an additional 5,058 shares during the last quarter. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.